

Luisa Guidi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770293/publications.pdf>

Version: 2024-02-01

108
papers

3,388
citations

117453

34
h-index

155451

55
g-index

109
all docs

109
docs citations

109
times ranked

4470
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Incident Colorectal Cancer in Inflammatory Bowel Disease. <i>Cancers</i> , 2022, 14, 721. | 1.7 | 5 |
| 2 | Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 313-320. | 1.4 | 1 |
| 3 | Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IG–IBD LIVE</scp> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109. | 1.9 | 25 |
| 4 | Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339. | 0.6 | 37 |
| 5 | Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 97-104. | 1.4 | 3 |
| 6 | Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066. | 1.4 | 34 |
| 7 | Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 853. | 1.0 | 22 |
| 8 | Dual Targeted Therapy in Patient With Extensive Crohn–s Disease: Different Response at Distinct Location. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e93-e94. | 0.9 | 1 |
| 9 | Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. <i>Italian Journal of Pediatrics</i> , 2021, 47, 18. | 1.0 | 12 |
| 10 | Serum triiodothyronine–to–thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 273-280. | 1.9 | 18 |
| 11 | Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. <i>Current Medical Research and Opinion</i> , 2020, 36, 7-8. | 0.9 | 5 |
| 12 | TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade. <i>Digestive and Liver Disease</i> , 2020, 52, 1188-1194. | 0.4 | 15 |
| 13 | Impact of COVID–19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high–volume Italian inflammatory bowel disease centre. <i>United European Gastroenterology Journal</i> , 2020, 8, 775-781. | 1.6 | 40 |
| 14 | Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 280-290. | 2.2 | 4 |
| 15 | The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579. | 0.9 | 51 |
| 16 | Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case–Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459. | 0.9 | 33 |
| 17 | Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639. | 0.4 | 36 |
| 18 | TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine. <i>EBioMedicine</i> , 2019, 41, 40-41. | 2.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1189-1197. | 1.6 | 31 |
| 20 | Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7. | 0.7 | 7 |
| 21 | Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018, 4, e000667. | 1.8 | 15 |
| 22 | Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- $\hat{\pm}$ on the Liver. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2199. | 1.8 | 62 |
| 23 | Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 751-759. | 1.3 | 14 |
| 24 | Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088. | 0.6 | 50 |
| 25 | Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358. | 0.4 | 42 |
| 26 | Watery stools and metabolic acidosis. <i>Internal and Emergency Medicine</i> , 2017, 12, 487-492. | 1.0 | 2 |
| 27 | The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243. | 0.9 | 116 |
| 28 | Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. <i>Digestive and Liver Disease</i> , 2017, 49, 997-1002. | 0.4 | 7 |
| 29 | Anti TNF- $\hat{\pm}$ therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233. | 1.3 | 78 |
| 30 | Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. <i>Drug, Healthcare and Patient Safety</i> , 2016, 8, 1. | 1.0 | 3 |
| 31 | Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 913-924. | 0.6 | 30 |
| 32 | What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 387. | 0.6 | 6 |
| 33 | Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 880-888. | 1.9 | 94 |
| 34 | Management of perianal fistulas in Crohn's disease: An up-to-date review. <i>World Journal of Gastroenterology</i> , 2015, 21, 1394. | 1.4 | 82 |
| 35 | Therapeutic drug monitoring of anti-TNF- $\hat{\pm}$ agents in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1107-1117. | 1.4 | 13 |
| 36 | Linking estrogen receptor $\hat{2}$ expression with inflammatory bowel disease activity. <i>Oncotarget</i> , 2015, 6, 40443-40451. | 0.8 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1368-1374. | 0.9 | 55 |
| 38 | 342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. <i>Gastroenterology</i> , 2014, 146, S-78-S-79. | 0.6 | 1 |
| 39 | Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor $\hat{\pm}$ agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. <i>Digestive and Liver Disease</i> , 2014, 46, 974-979. | 0.4 | 64 |
| 40 | Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 852-858. | 0.6 | 54 |
| 41 | Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014, 46, 290-291. | 0.4 | 1 |
| 42 | Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e623-e629. | 0.6 | 85 |
| 43 | Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 769-779. | 0.6 | 114 |
| 44 | Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\hat{\pm}$ agents. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 113-119. | 0.6 | 68 |
| 45 | Adalimumab in active ulcerative colitis: A $\hat{\pm}$ real-life $\hat{\pm}$ observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743. | 0.4 | 72 |
| 46 | A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 421-426. | 0.6 | 18 |
| 47 | Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF- $\hat{\pm}$ agents: Effects of combined therapy with immunosuppressants. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 301-307. | 0.6 | 86 |
| 48 | AID in aging and autoimmune diseases. <i>Autoimmunity</i> , 2013, 46, 168-175. | 1.2 | 11 |
| 49 | FOXP3 ⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF Agents. <i>BioMed Research International</i> . 2013. 2013. 1-10. | 0.9 | 31 |
| 50 | Infliximab in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1065-1072. | 0.9 | 66 |
| 51 | Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. <i>Drug Design, Development and Therapy</i> , 2013, 7, 289. | 2.0 | 8 |
| 52 | Mucosal healing in ulcerative colitis: surveillance or colectomy?. <i>Annals of Gastroenterology</i> , 2013, 26, 355. | 0.4 | 1 |
| 53 | Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013, 22, 21-5. | 0.5 | 13 |
| 54 | Ileal Crohn Disease: Mural Microvasculature Quantified with Contrast-enhanced US Correlates with Disease Activity. <i>Radiology</i> , 2012, 262, 680-688. | 3.6 | 74 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Ileal Crohn's disease: CEUS determination of activity. <i>Abdominal Imaging</i> , 2012, 37, 359-368. | 2.0 | 21 |
| 56 | In Vivo and In Vitro Immune Response to Pandemic Influenza 2009 H1N1 Vaccine in Inflammatory Bowel Disease Patients on Anti TNF-Alpha Treatment. <i>Gastroenterology</i> , 2011, 140, S-274. | 0.6 | 0 |
| 57 | Response to Influenza Vaccine a/H1N1 2009 in Patients With Inflammatory Bowel Disease on Anti TNF-Alpha Therapy. <i>Gastroenterology</i> , 2011, 140, S-274. | 0.6 | 0 |
| 58 | Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35. | 2.4 | 316 |
| 59 | P.1.218: INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA TREATMENT: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE IN VIVO AND IN VITRO. <i>Digestive and Liver Disease</i> , 2011, 43, S220. | 0.4 | 0 |
| 60 | Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1376-1379.e1. | 1.5 | 54 |
| 61 | Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S1978. | 0.4 | 0 |
| 62 | Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1435-1444. | 1.0 | 66 |
| 63 | Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. <i>European Journal of Immunology</i> , 2011, 41, 1120-1131. | 1.6 | 72 |
| 64 | The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. <i>Journal of Clinical Apheresis</i> , 2011, 26, 332-337. | 0.7 | 23 |
| 65 | Update on the management of inflammatory bowel disease: specific role of adalimumab. <i>Clinical and Experimental Gastroenterology</i> , 2011, 4, 163. | 1.0 | 29 |
| 66 | A Case of Hereditary Hemorrhagic Telangiectasia Associated With Crohn's Disease Successfully Treated With Infliximab. <i>American Journal of Gastroenterology</i> , 2010, 105, 1904. | 0.2 | 4 |
| 67 | CT findings and clinical activity in Crohn's disease. <i>Clinical Imaging</i> , 2009, 33, 123-129. | 0.8 | 26 |
| 68 | From initial case report to randomized clinical trial through 20 years of research in periodontal therapy. <i>Journal of Clinical Periodontology</i> , 2009, 36, 39-43. | 2.3 | 1 |
| 69 | Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy. <i>European Radiology</i> , 2009, 19, 2432-2440. | 2.3 | 45 |
| 70 | Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. <i>American Journal of Gastroenterology</i> , 2009, 104, 1575-1586. | 0.2 | 37 |
| 71 | W1049 Quantification of Microvascular Activation in Ileal Crohn's Disease By Software Elaboration Data Applied to CEUS: Correlation with Biological Activity Indexes. <i>Gastroenterology</i> , 2009, 136, A-643. | 0.6 | 0 |
| 72 | Internet use among inflammatory bowel disease patients: an Italian multicenter survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1036-1041. | 0.8 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. <i>Techniques in Coloproctology</i> , 2008, 12, 111-117. | 0.8 | 38 |
| 74 | Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1168-1170. | 0.9 | 21 |
| 75 | Treatment of Crohn's disease with colony-stimulating factors: An overview. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 927-934. | 0.9 | 5 |
| 76 | Citation classics in periodontology: a controlled study. <i>Journal of Clinical Periodontology</i> , 2007, 34, 349-358. | 2.3 | 37 |
| 77 | Multidetector CT enteroclysis versus barium enteroclysis with methylcellulose in patients with suspected small bowel disease. <i>European Radiology</i> , 2006, 16, 1527-1536. | 2.3 | 52 |
| 78 | Increased Levels of NF- κ B Inhibitors ($I\kappa$ B α and $I\kappa$ B β) in the Intestinal Mucosa of Crohn's Disease Patients during Infliximab Treatment. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 155-164. | 1.0 | 26 |
| 79 | Increased carotid intima-media thickness in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 839-846. | 1.9 | 97 |
| 80 | Duodenoscopy & Capsule Endoscopy: A New Method to "Staging" Coeliac Disease. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB162. | 0.5 | 0 |
| 81 | Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2004, 36, 528-532. | 0.4 | 14 |
| 82 | Role of immune responsiveness and DNA repair capacity genes in ageing. <i>Ageing Research Reviews</i> , 2004, 3, 143-151. | 5.0 | 15 |
| 83 | DNA damage recognition and repair capacities in human naive and memory T cells from peripheral blood of young and elderly subjects. <i>Mechanisms of Ageing and Development</i> , 2003, 124, 517-524. | 2.2 | 22 |
| 84 | Interleukin-6 release in the hepatic blood outflow during normothermic liver ischaemia in humans. <i>Digestive and Liver Disease</i> , 2003, 35, 409-415. | 0.4 | 13 |
| 85 | Role of DNA-dependent protein kinase (DNA-PK), a protein with multiple intracellular functions, in cells of the ageing immune system. <i>Advances in Cell Aging and Gerontology</i> , 2002, , 217-230. | 0.1 | 0 |
| 86 | The DNA repair protein ku is involved in gp130-mediated signal transduction events in PBMC from young but not from elderly subjects. <i>Experimental Gerontology</i> , 2002, 37, 321-328. | 1.2 | 7 |
| 87 | Small bowel diseases. <i>Rays</i> , 2002, 27, 3-10. | 0.2 | 0 |
| 88 | Modulation of X-ray-induced damage recognition and repair in ageing human peripheral blood mononuclear cells by an interleukin-6-type cytokine. <i>Mechanisms of Ageing and Development</i> , 2001, 121, 5-19. | 2.2 | 5 |
| 89 | Role of DNA-dependent protein kinase in recognition of radiation-induced DNA damage in human peripheral blood mononuclear cells. <i>International Immunology</i> , 2001, 13, 791-797. | 1.8 | 13 |
| 90 | Small bowel Gd-enhanced MRI at 0.5T using enteroclysis with a superparamagnetic oral agent in Crohn's disease. <i>Gastroenterology</i> , 2000, 118, A1338. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Neuropeptide Y Plasma Levels and Immunological Changes during Academic Stress. <i>Neuropsychobiology</i> , 1999, 40, 188-195. | 0.9 | 32 |
| 92 | Effect of age on DNA binding of the ku protein in irradiated human peripheral blood mononuclear cells (PBMC). <i>Experimental Gerontology</i> , 1999, 34, 645-658. | 1.2 | 30 |
| 93 | Characteristics of Gastric-Vein Lymphocytes with Regard to the Immune Response to <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 757-764. | 0.6 | 0 |
| 94 | Cell proliferation and ku protein expression in ageing humans. <i>Mechanisms of Ageing and Development</i> , 1998, 100, 197-208. | 2.2 | 15 |
| 95 | Changes in the amount and level of phosphorylation of p56lck in PBL from aging humans. <i>Mechanisms of Ageing and Development</i> , 1998, 102, 177-186. | 2.2 | 17 |
| 96 | The Effect of Zinc and Vitamin A Supplementation on Immune Response in an Older Population. <i>Journal of the American Geriatrics Society</i> , 1998, 46, 19-26. | 1.3 | 140 |
| 97 | Psychoneuroimmunology and Aging. <i>Gerontology</i> , 1998, 44, 247-261. | 1.4 | 26 |
| 98 | Plasma Thrombin-Antithrombin Complexes, Latent Coagulation Disorders and Metastatic Spread in Lung Cancer: A Longitudinal Study. <i>Oncology</i> , 1996, 53, 455-460. | 0.9 | 14 |
| 99 | Lymphocyte Proliferative Response to <i>Helicobacter pylori</i> CagA Protein in Patients with Duodenal Ulcer or Gastritis. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 81-82. | 1.1 | 1 |
| 100 | Psychological status, life and social conditions: A study in a population of institutionalized elderly people. <i>International Journal of Geriatric Psychiatry</i> , 1993, 8, 419-426. | 1.3 | 1 |
| 101 | Assay, Isolation and Characterization of Circulating Immune Complexes from Serum of Gastrointestinal Cancer, Stage III and IV Melanoma and Chronic Inflammatory Bowel Disease Patients. <i>Oncology</i> , 1993, 50, 27-34. | 0.9 | 6 |
| 102 | The efficacy of chemotherapy with mebendazole in human cystic echinococcosis: long-term follow-up of 52 patients. <i>Annals of Tropical Medicine and Parasitology</i> , 1992, 86, 249-256. | 1.6 | 29 |
| 103 | Latent Coagulation Disorders Evaluated by the Assay of Plasma Thrombin-Antithrombin III Complexes in a Large Series of "Solid Tumours". <i>Oncology</i> , 1992, 49, 426-430. | 0.9 | 7 |
| 104 | Immune parameters in a population of institutionalized elderly subjects: influence of depressive disorders and endocrinological correlations. <i>Mechanisms of Ageing and Development</i> , 1991, 60, 1-12. | 2.2 | 12 |
| 105 | Impairment of lymphocyte activities in depressed aged subjects. <i>Mechanisms of Ageing and Development</i> , 1991, 60, 13-24. | 2.2 | 40 |
| 106 | Psychological Status of Institutionalized Aged: Influences on Immune Parameters and Endocrinological Correlates. <i>International Journal of Neuroscience</i> , 1990, 51, 279-281. | 0.8 | 5 |
| 107 | Soluble immunosuppressor factors in human cancer. <i>Clinical Immunology Newsletter</i> , 1988, 9, 124-127. | 0.1 | 0 |
| 108 | Myasthenia gravis, thymectomy, and antiacetylcholine receptor antibody. <i>Journal of Neurology</i> , 1980, 224, 9-15. | 1.8 | 38 |